Evaluation of the effectiveness of platinib in leukemia therapy

Pralsetinib, as a highly selective BCR-ABL1 TKI (tyrosine kinase inhibitor), has attracted widespread attention in the field of leukemia treatment in recent years. Especially for patients with chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), platinib has shown significant therapeutic effects.

CMLIt is a malignant tumor that affects the blood and bone marrow and is characterized by the production of large numbers of immature white blood cells in the bone marrow. These cells accumulate in the bone marrow, inhibit normal hematopoietic function, and may spread throughout the body through the blood, causing patients to experience symptoms such as anemia, easy bleeding, infection, and organ infiltration. Traditional treatment methods such as chemotherapy and radiotherapy have major side effects. The emergence of platinib has brought new treatment options to CML patients.

Platinib can precisely act on theBCR-ABL1 fusion protein and block its signaling pathway, thereby effectively inhibiting the proliferation and spread of leukemia cells. More importantly, platinib has shown strong inhibitory effects on a variety of drug-resistant mutations, including the T315I mutation. This means that even if patients develop resistance to other TKI drugs, platinib may still bring them treatment hope.

Platinib has demonstrated impressive efficacy in multiple clinical trials. Complete hematologic response, major cytogenetic response, and major molecular response rates were all high with platinib treatment in patients with CML who were resistant or intolerant to at least two prior TKIs. Especially for patients with T315I mutation, the therapeutic effect of platinib is particularly significant.

It is worth noting that platinib may also produce some side effects during treatment, such as high blood pressure, rash, abdominal pain, etc. Therefore, when using platinib, doctors need to adjust the dosage according to the patient's specific situation to ensure the safety and effectiveness of the treatment.